Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is estimated to affect approximately 1 in 50,000 people worldwide. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia. This article will provide an overview of Friedreich ataxia, including its causes, symptoms, diagnosis, and treatments.
Friedreich ataxia is an inherited disorder that affects the nervous system and causes progressive physical and cognitive disability. It is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
The symptoms of Friedreich ataxia vary from person to person, but usually appear in childhood or adolescence. Common symptoms include: • Progressive loss of coordination, balance, and muscle strength • Loss of sensation in the extremities • Slurred speech and difficulty swallowing • Vision problems • Hearing loss • Heart problems • Fatigue • Scoliosis • Diabetes
Friedreich ataxia is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
Friedreich ataxia is usually diagnosed through a combination of physical examination, neurological testing, and genetic testing. Physical examination may reveal signs of muscle weakness, coordination problems, and scoliosis. Neurological testing may reveal impaired reflexes, muscle weakness, and balance problems. Genetic testing can confirm the presence of the FXN gene mutation.
There is currently no cure for Friedreich ataxia, but there are treatments available to help manage the symptoms. Treatment may include physical therapy, occupational therapy, speech therapy, and medications to help manage pain, fatigue, and other symptoms. Additionally, there are clinical trials underway to investigate potential treatments for Friedreich ataxia.
Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Diagnosis involves physical examination, neurological testing, and genetic testing, and treatments may include physical therapy, occupational therapy, speech therapy, and medications. While there is currently no cure for Friedreich ataxia, there are treatments available to help manage the symptoms and clinical trials underway to investigate potential treatments.
1.
Q&A: When will individuals be able to receive customized cancer vaccines?
2.
Canadian Group Calls for Earlier Colorectal Cancer Screening
3.
Children living near oil and gas wells face higher risk of rare leukemia, studies show
4.
Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.
5.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
1.
Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer
2.
Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics
3.
The Benefits and Side Effects of Bortezomib in the Fight Against Cancer
4.
Personalized Tumor Ecological Landscapes in Oncology
5.
Unmasking the Subtle Symptoms of Colon Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Immunotherapy: A New Era in Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation